LSUHSC research identifies key contributor to Alzheimer's disea...(icans and it is projected that the numb...)
Navigation Links
LSUHSC research identifies key contributor to Alzheimer's disease process
Date:11/13/2008
icans and it is projected that the number could more than triple to 16 million by mid-century.
"The goal of these neuroscience research studies is to further our understanding of the molecular biology and genetic mechanisms associated with Alzheimer's Disease and to advance the design of therapeutic strategies to counteract this common and tragic neurological disorder," said Dr. Lukiw.
'/>"/>
| Contact: Leslie Capo lcapo@lsuhsc.edu 504-568-4806 Louisiana State University Health Sciences Center Source:Eurekalert |
Related biology news :
1. LSUHSC awarded patent for compound inhibiting cancer and other diseases
2. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
3. LSUHSCs Lazartigues awarded $1.2 million grant
4. LSUHSC awarded $10M+ COBRE grant
5. Compact research freezers to debut in space
6. Space researchers developing tool to help disoriented pilots
7. Montana State researchers receive grant to study algae as a source of biofuel
8. Einstein researchers develop a new way to study how breast cancer spreads
9. Queens University Belfast researchers trace octopuses family tree
10. K-State research: Freshwater pollution costs US at least $4.3 billion a year
11. UD researchers show that plants can accumulate nanoparticles in tissues
Post Your Comments:
Breaking Biology News(10 mins):Plate-eating good: Université de Montréal professor designs edible tableware 2Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Errors in diagnosis of depression lead to over and under diagnosis in primary care 53122 1Errors in diagnosis of depression lead to over and under diagnosis in primary care 53122 2Little known protein found to be key player 9419 1Little known protein found to be key player 9419 2Jet propelled imaging for an ultrafast light source 9415 1Jet propelled imaging for an ultrafast light source 9415 2Jet propelled imaging for an ultrafast light source 9415 3Jet propelled imaging for an ultrafast light source 9415 4Jet propelled imaging for an ultrafast light source 9415 5Jet propelled imaging for an ultrafast light source 9415 6
Other Biology News:Are we killing the world's oceans? 2Why aren't humans furry? Stone-Age moms could be the answer 2Antibody therapy prevents type 1 diabetes in mice 2
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2
[0] Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project[1] Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
Other Biology Technology:The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 2The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C. 3Helix BioPharma reports Q2 2008 highlights, financial results 2Helix BioPharma reports Q2 2008 highlights, financial results 3Helix BioPharma reports Q2 2008 highlights, financial results 4Helix BioPharma reports Q2 2008 highlights, financial results 5Helix BioPharma reports Q2 2008 highlights, financial results 6Helix BioPharma reports Q2 2008 highlights, financial results 7Helix BioPharma reports Q2 2008 highlights, financial results 8Helix BioPharma reports Q2 2008 highlights, financial results 9Helix BioPharma reports Q2 2008 highlights, financial results 10Helix BioPharma reports Q2 2008 highlights, financial results 11Helix BioPharma reports Q2 2008 highlights, financial results 12Helix BioPharma reports Q2 2008 highlights, financial results 13Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences 2Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences 3Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences 4
The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems' CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.Helix BioPharma reports Q2 2008 highlights, financial resultsHalozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |